Navigation Links
GeoPharma to Present at EdgeWater Research Partners Conference
Date:4/8/2008

Largo, Fla., April 8, 2008 /PRNewswire-FirstCall/ -- GeoPharma, Inc. (Nasdaq: GORX) announced that the company will present today at the EdgeWater Research Partners Spring Conference being held at the Grand Hyatt in Denver, Colorado at 2:25 MT.

"We are thoroughly pleased to have GeoPharma present at the spring conference," said EdgeWater President David Lavigne. "GeoPharma has a unique story with a thriving Manufacturing and Distribution business. We expect further positive developments in their Specialty Pharma business with several antibiotic drugs soon to enter into production. Furthermore, the continued development of their Early Stage Ovarian Cancer Diagnostic Device and the value it may add if approved, has not been factored into their current valuation."

EdgeWater Research Partners recently issued a Quarterly update to their Initial Coverage Report on GeoPharma which is currently the featured report on the GeoPharma website. The EdgeWater report and other research reports can be found on the Investor Relations Home Page at http://www.GeoPharmainc.com .

ABOUT EDGEWATER RESEARCH PARTNERS LLC:

EdgeWater Research Partners LLC. is an independent subscription based micro cap stock research company. Subscribers receives a monthly micro cap stock newsletter, in addition to individual company research reports and updates similar to the one's issued on GeoPharma. Annual subscriptions to EdgeWater Research services are available at http://www.edgewaterresearch.com

ABOUT GEOPHARMA, INC.:

GeoPharma, Inc. is a rapidly growing Bio/Pharma company with a diversified business model participating in 3 main market segments: Specialty Pharma, Manufacturing, and Distribution. The Specialty Pharma division specializes in the formulation of generic drugs for human and veterinary usage and the development of medical devices used by oncologists and other medical professionals. The Manufacturing and Distribution divisions, manufacture, package, and distribute generic drugs, nutraceuticals, cosmetics, and functional food products for companies worldwide.

GeoPharma's growth strategy is to capitalize on its research and manufacturing expertise to develop medical devices and high margin generic drug products for niche markets with high barriers to entry. GeoPharma's competitive advantage in these areas is in its ability to navigate the challenges that such market pursuits present effectively.

Currently GeoPharma employs nearly 300 people and operates facilities in Florida, Maryland, Pennsylvania, Nevada, Rhode Island, and Texas utilizing over 330,000 Sq. Ft. of office, warehouse, manufacturing and laboratory facilities.

For further information visit the GeoPharma website at http://www.GeoPharmainc.com.

FORWARD-LOOKING STATEMENTS

This press release may contain statements, which constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those regarding the company and its subsidiaries' expectations, intentions, strategies and beliefs pertaining to future performance. All statements contained herein are based upon information available to the company's management as of the date hereof, and actual results may vary based upon future events, both within and without management's control. Important factors that could cause such differences are described in the company's periodic filings with the Securities and Exchange Commission.


'/>"/>
SOURCE GeoPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GeoPharma Announces Record Revenues in Third Quarter Results
2. GeoPharma Announces Third Quarter Conference Call
3. GeoPharma, Inc. Receives FDA Approval to Manufacture and Distribute Carprofen
4. MaxCyte to Present at BIO-Europe Spring 2008 Conference
5. Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences
6. Prometic to present at the American Chemical Society
7. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
8. Parks Associates Digital Health Analyst to Present Latest Research and Forecasts at ATA Show
9. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
10. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
11. DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... -- ATCC, the premier global biological materials resource and ... life science researchers that are working to address the ... CDC website . --> CDC website ... single-stranded RNA virus of the Flaviviridae family, genus Flavivirus, ... Viruses. Zika virus is transmitted to humans primarily through ...
(Date:2/5/2016)... , February 5, 2016 Amarantus ... biotechnology company focused on developing products for Regenerative Medicine, ... Rare Pediatric Disease Designation (RPDD) from the US Food ... with MANF. MANF was previously granted orphan drug designation ... --> Amarantus BioScience Holdings, Inc. (OTCQB: ...
(Date:2/4/2016)... 2016 - New FDA action date of ... FDA action date of July 22, 2016   ... 22, 2016   - Lifitegrast has ... indicated for the treatment of signs and symptoms of dry eye ... potential to be the only product approved in the U.S. in the past decade indicated ...
(Date:2/4/2016)... Falls Church, VA (PRWEB) , ... ... ... a first-year cybersecurity conference presented by Bloomsburg University’s Digital Forensics Club, takes ... Bloomsburg, PA. The two-day event features 20+ speakers and activities such as ...
Breaking Biology Technology:
(Date:1/25/2016)... -- Glencoe Software, the world-leading supplier of image data management ... the data management solution OMERO Plus for the newly ... Photo - http://photos.prnewswire.com/prnh/20160125/325328LOGO ... Phenotypic analysis measures the characteristics and behavior of cells, ... such as health and disease, the presence or absence ...
(Date:1/20/2016)... , Jan. 20, 2016 A market that ... directly benefit from the explosion in genomics knowledge. Learn ... Sound Research. A range of dynamic trends are pushing ... - personalized medicine - pharmacogenomics - pathogen evolution - ... large markets - greater understanding of the role of ...
(Date:1/15/2016)... , Jan. 15, 2016 Recent publicized breaches ... to find new ways to ensure data security and ... iOS and Android that ties a ... transforming it into a hardware authorization token. Customer service ... their fingerprint on their KodeKey enabled device to verify ...
Breaking Biology News(10 mins):